Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
No Thumbnail
Authors
Bila, JelenaSretenović, Aleksandra
Jelicić, Jelena
Tošić, Nataša
Marjanović, Irena
Fekete, Marija Dencic
Antić, Darko
Todorovic-Balint, Milena
Marković, Olivera
Milojević, Zoran
Radojković, Milica
Trajković, Goran
Purić, Mila
Pavlović, Sonja
Mihaljević, Biljana
Article (Published version)
Metadata
Show full item recordAbstract
Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26....1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
Keywords:
Treatment / Prognosis / Multiple myeloma / Immunomodulatory drugs / CRBN expressionSource:
Clinical Lymphoma Myeloma & Leukemia, 2016, 16, 11, 610-615Publisher:
- CIG Media Group, Lp, Dallas
Funding / projects:
- Rare Diseases:Molecular Pathophysiology, Diagnostic and Therapeutic Modalities and Social, Ethical and Legal Aspects (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41004)
DOI: 10.1016/j.clml.2016.08.007
ISSN: 2152-2650
PubMed: 27618360
WoS: 000389015600003
Scopus: 2-s2.0-84994520453
Collections
Institution/Community
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Bila, Jelena AU - Sretenović, Aleksandra AU - Jelicić, Jelena AU - Tošić, Nataša AU - Marjanović, Irena AU - Fekete, Marija Dencic AU - Antić, Darko AU - Todorovic-Balint, Milena AU - Marković, Olivera AU - Milojević, Zoran AU - Radojković, Milica AU - Trajković, Goran AU - Purić, Mila AU - Pavlović, Sonja AU - Mihaljević, Biljana PY - 2016 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/962 AB - Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. PB - CIG Media Group, Lp, Dallas T2 - Clinical Lymphoma Myeloma & Leukemia T1 - Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma EP - 615 IS - 11 SP - 610 VL - 16 DO - 10.1016/j.clml.2016.08.007 ER -
@article{ author = "Bila, Jelena and Sretenović, Aleksandra and Jelicić, Jelena and Tošić, Nataša and Marjanović, Irena and Fekete, Marija Dencic and Antić, Darko and Todorovic-Balint, Milena and Marković, Olivera and Milojević, Zoran and Radojković, Milica and Trajković, Goran and Purić, Mila and Pavlović, Sonja and Mihaljević, Biljana", year = "2016", abstract = "Within a personalized treatment approach in multiple myeloma (MM), the prognostic significance of cereblon (CRBN) expression was analyzed in 92 newly diagnosed patients. In patients treated with thalidomide-based combinations, CRBN expression significantly affected the treatment response (P = .028) and progression free survival (P = .017). With implications for the treatment outcome, measurement of CRBN expression might represent an additional prognostic tool in a personalized treatment approach. Background: To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon (CRBN) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods: The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results: A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression (P = .006), mainly in the patients treated with thalidomide (P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients (P = .012). Conclusion: CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.", publisher = "CIG Media Group, Lp, Dallas", journal = "Clinical Lymphoma Myeloma & Leukemia", title = "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma", pages = "615-610", number = "11", volume = "16", doi = "10.1016/j.clml.2016.08.007" }
Bila, J., Sretenović, A., Jelicić, J., Tošić, N., Marjanović, I., Fekete, M. D., Antić, D., Todorovic-Balint, M., Marković, O., Milojević, Z., Radojković, M., Trajković, G., Purić, M., Pavlović, S.,& Mihaljević, B.. (2016). Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia CIG Media Group, Lp, Dallas., 16(11), 610-615. https://doi.org/10.1016/j.clml.2016.08.007
Bila J, Sretenović A, Jelicić J, Tošić N, Marjanović I, Fekete MD, Antić D, Todorovic-Balint M, Marković O, Milojević Z, Radojković M, Trajković G, Purić M, Pavlović S, Mihaljević B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. in Clinical Lymphoma Myeloma & Leukemia. 2016;16(11):610-615. doi:10.1016/j.clml.2016.08.007 .
Bila, Jelena, Sretenović, Aleksandra, Jelicić, Jelena, Tošić, Nataša, Marjanović, Irena, Fekete, Marija Dencic, Antić, Darko, Todorovic-Balint, Milena, Marković, Olivera, Milojević, Zoran, Radojković, Milica, Trajković, Goran, Purić, Mila, Pavlović, Sonja, Mihaljević, Biljana, "Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma" in Clinical Lymphoma Myeloma & Leukemia, 16, no. 11 (2016):610-615, https://doi.org/10.1016/j.clml.2016.08.007 . .